Advertisement

Topics

How will the timing of BPCI Act 180-day notice affect biosimilars?

18:38 EDT 4 May 2017 | Generics and Biosimilars Initiative

On 26 April 2017, the US Supreme Court heard oral arguments in Amgen vs Sandoz. The case has come to the Supreme Court after the Court of Appeals for the Federal Circuit made the controversial ruling that the so-called ‘patent dance’ was optional, but also that the 180-day notice could only be given after the 12-year exclusivity period ended.

Original Article: How will the timing of BPCI Act 180-day notice affect biosimilars?

NEXT ARTICLE

More From BioPortfolio on "How will the timing of BPCI Act 180-day notice affect biosimilars?"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...